Research coauthored by RTI Health Solutions researchers will be presented at the ESMO 2019 Congress.
Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis KL, Bakker NA, Thakrar B, Taylor A, Feliciano J.
Continuation of annual screening mammograms and breast-cancer mortality in women over 70. Garcia de Albeniz Martinez X, Hsu J, Hernan M.
Xabier Garcia de Albeniz Martinez will be presenting this research in person.